Synthon announces European approvals for Eplerenone
19-Sep-2011
- Netherlands
Synthon's Eplerenone is a fully generic and bioequivalent version of Pfizer’s Inspra® tablets.
European sales of Eplerenone were 109 million Euros (MAT June 2011) based on IMS Midas data. Synthon’s Eplerenone is part of a rich pipeline of research projects and pending regulatory applications.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.